Protagonist Therapeutics, Inc (PTGX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| License and collaboration revenue | 5,546 | 28,321 | 4,675 | 4,167 |
| Research and development | 37,036 | 35,893 | 35,970 | 33,520 |
| General and administrative | 10,551 | 11,738 | 10,158 | 9,440 |
| Total operating expenses | 47,587 | 47,631 | 46,128 | 42,960 |
| (loss) income from operations | -42,041 | -19,310 | -41,453 | -38,793 |
| Interest income | 7,406 | 7,573 | 7,682 | 7,404 |
| Other income, net | 36 | 82 | 141 | 97 |
| (loss) income before income tax expense (benefit) | -34,599 | -11,655 | -33,630 | -31,292 |
| Income tax expense (benefit) | 172 | - | -420 | -676 |
| Net (loss) income | -34,771 | -11,655 | -33,210 | -30,616 |
| Earnings per share, basic | -0.55 | -0.19 | -0.54 | -0.5 |
| Earnings per share, diluted | -0.55 | -0.19 | -0.54 | -0.5 |
| Weighted average number of shares outstanding, basic | 63,510,537 | 62,963,806 | 61,767,934 | 61,305,289 |
| Weighted average number of shares outstanding, diluted | 63,510,537 | 62,963,806 | 61,767,934 | 61,305,289 |